Patient-reported Outcome Measures for Angioedema: A Literature Review

Authors

  • Anna Trier Heiberg Brix Department of Clinical Genetics, Odense University Hospital, DK-5000 Odense C, Denmark
  • Henrik Balle Boysen
  • Karsten Weller
  • Teresa Caballero
  • Anette Bygum

DOI:

https://doi.org/10.2340/00015555-3807

Keywords:

hereditary angioedema, angioedema, patient-reported outcome measure

Abstract

Angioedema and hereditary angioedema are characterized by swelling of the subcutaneous and/or submucosal tissue, resulting in localized oedema. The rarity, but also the diverse clinical presentation, of these conditions can be challenging regarding diagnosis, treatment, and management. Patient-reported outcome measures (PROMs) are data received directly from the patient, providing the patient’s perspective on various subjects regarding health and well-being. PROMs can be helpful tools to optimize treatment and long-term management of conditions. A major challenge regarding the consistent use of PROMs in clinical settings in Scandinavia is language availability; many of the validated PROMs for hereditary angioedema and angioedema lack translations into the Nordic languages. The litterature search yielded 9 different PROM tools for angioedema and hereditary angioedema. Five were found suitable for use in clinical practice in Europe. Even though several PROMs exist they are not used consistent. Accessible electronic PROMs and careful planning is required to implement PROMs optimally in routine care processes.

Downloads

Download data is not yet available.

References

Rye Rasmussen EH, Bindslev-Jensen C, Bygum A. Angioedema - assessment and treatment. Tidsskr Nor Laegeforen 2012; 132: 2391-2395.

DOI: https://doi.org/10.4045/tidsskr.12.0470

Belbézier A, Bocquet A, Bouillet L. Idiopathic angioedema: current challenges. J Asthma Allergy 2020; 13: 137-144.

DOI: https://doi.org/10.2147/JAA.S205709

Pall AH, Lomholt AF, von Buchwald C, Bygum A, Rasmussen ER. Clinical features and disease course of primary angioedema patients in a tertiary care hospital. J Asthma Allergy 2020; 13: 225-236.

DOI: https://doi.org/10.2147/JAA.S245161

Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, Cicardi M. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175: 1065-1070.

DOI: https://doi.org/10.1503/cmaj.060535

Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69: 602-616.

DOI: https://doi.org/10.1111/all.12380

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018; 73: 1393-1414.

DOI: https://doi.org/10.1111/all.13397

Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein JA. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol 2017; 31: 1056-1063

DOI: https://doi.org/10.1111/jdv.14075

Bygum A. Hereditary angio-oedema for dermatologists. Dermatology 2019; 235: 263-275.

DOI: https://doi.org/10.1159/000500196

Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med 2020; 382: 1136-1148.

DOI: https://doi.org/10.1056/NEJMra1808012

Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130: 692-697.

DOI: https://doi.org/10.1016/j.jaci.2012.05.055

Bork K, Wulff K, Rossmann H, Steinmüller-Magin L, Braenne I, Witzke G, Hardt J. Hereditary angioedema cosegregating with a novel kininogen1 gene mutation changing the N- terminal cleavage site of bradykinin. Allergy 2019; 74: 2479-2481.

DOI: https://doi.org/10.1111/all.13869

Ariano A, D'Apolito M, Bova M, Bellanti F, Loffredo S, D'Andrea G, et al. A myoferlin gain-of-function variant associates with a new type of hereditary angioedema. Allergy 2020; 75: 2989-2992.

DOI: https://doi.org/10.1111/all.14454

Aabom A, Andersen KE, Perez-Fernández E, Caballero T, Bygum A. Health-related quality of life in Danish patients with hereditary angioedema. Acta Derm Venereol 2015; 95: 225-226.

DOI: https://doi.org/10.2340/00015555-1835

Nordenfelt P, Nilsson M, Lindfors A Wahlgren CF, Björkander J. Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden. Allergy Asthma Proc 2017; 38: 447-455.

DOI: https://doi.org/10.2500/aap.2017.38.4087

Caballero T, Prior N. Burden of illness and quality-of-life measures in angioedema conditions. Immunol Allergy Clin North Am 2017; 37: 597-616.

DOI: https://doi.org/10.1016/j.iac.2017.04.005

Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact and control and how to assess them in patients with hereditary angioedema. Front Med 2017; 4: 212.

DOI: https://doi.org/10.3389/fmed.2017.00212

Caballero T, Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. Allergy Asthma Proc 2014; 35: 47-53.

DOI: https://doi.org/10.2500/aap.2013.34.3685

Fouche AS, Saunders EF, Craig T. Depression and anxiety in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2014; 112: 371-375.

DOI: https://doi.org/10.1016/j.anai.2013.05.028

Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ 2015; 350: g7818.

DOI: https://doi.org/10.1136/bmj.g7818

Santana MJ, Feeny D. Framework to assess the effects of using patient-reported outcome measures in chronic care management. Qual Life Res 2014; 23: 1505-1513.

DOI: https://doi.org/10.1007/s11136-013-0596-1

Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy 2013; 68: 1185-1192.

DOI: https://doi.org/10.1111/all.12209

Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy 2012; 67: 1289-1298.

DOI: https://doi.org/10.1111/all.12007

Weller K, Donoso T, Magerl M, Aygören-Pürsün E, Staubach P, Martinez-Saguer I, et al. Development of the Angioedema Control Test - a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 2020; 75: 1165-1177.

DOI: https://doi.org/10.1111/all.14144

Weller K, Donoso T, Magerl M, Aygören-Pürsün E, Staubach P, Martinez-Saguer I, et al. Validation of the Angioedema Control Test (AECT) - a patient-reported outcome instrument for assessing angioedema control. J Allergy Clin Immunol Pract 2020; 8: 2050-2057.e4.

DOI: https://doi.org/10.1016/j.jaip.2020.02.038

João Forjaz M, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, Caballero T; DV-HAE-QoL study group. HAE-AS, a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency. J Investig Allergol Clin Immunol 2020 Jan 14 [online ahead of print].

DOI: https://doi.org/10.18176/jiaci.0479

Prior N, Remor E, Pérez-Fernández E, Caminoa M, Gómez-Traseira C, Gayá F, et al. Psychometric field study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. J Allergy Clin Immunol Pract 2016; 4: 464-473.

DOI: https://doi.org/10.1016/j.jaip.2015.12.010

Bonner N, Abetz-Webb L, Renault L, Caballero T, Longhurst H, Maurer M, et al. Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies. Health Qual Life Outcomes 2015; 13: 92.

DOI: https://doi.org/10.1186/s12955-015-0292-7

Busse PJ, Christiansen SC, Birmingham JM, Overbey JR, Banerji A, Otani IM, et al. Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. J Allergy Clin Immunol Pract 2019; 7: 1679-1683.

DOI: https://doi.org/10.1016/j.jaip.2018.11.042

Vernon MK, Rentz AM, Wyrwich KW, White MV, Grienenberger A. Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema. Qual Life Res 2009; 18: 929-939.

DOI: https://doi.org/10.1007/s11136-009-9509-8

Maurer M, Magerl M, Ansotegui I, Aygören-Pürsün E, Betschel S, Bork K, et al. The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update. World Allergy Organ J 2018; 11: 5.

DOI: https://doi.org/10.1186/s40413-017-0180-1

Agboola F, Lubinga S, Carlson J, Lin GA, Dreitlein WB, Pearson SD. The effectiveness and value of lanadelumab and C1 esterase inhibitors for prophylaxis of hereditary angioedema attacks. J Manag Care Spec Pharm 2019; 25: 143-148.

DOI: https://doi.org/10.18553/jmcp.2019.25.2.143

Engel-Yeger B, Farkas H, Kivity S, Veszeli N, K?halmi KV, Kessel A. Health-related quality of life among children with hereditary angioedema. Pediatr Allergy Immunol 2017; 28: 370-376.

DOI: https://doi.org/10.1111/pai.12712

Aabom A, Nguyen D, Fisker N, Bygum A. Health-related quality of life in Danish children with hereditary angioedema. Allergy Asthma Proc 2017; 38: 440-446.

DOI: https://doi.org/10.2500/aap.2017.38.4093

Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3: 329-341.

DOI: https://doi.org/10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2

Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-949.

DOI: https://doi.org/10.1111/j.1365-2133.1995.tb16953.x

Kreiberg KB, Bygum A. Reporting through smartphone application results in detailed data on acquired and hereditary angioedema attacks. Allergy 2019; 74: 1800-1802.

DOI: https://doi.org/10.1111/all.13792

WHO. (accessed 2020 Jul 31). Available from: https: //www.who.int/substance_abuse/research_tools/translation/en/.

Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000; 25: 3186-3191.

DOI: https://doi.org/10.1097/00007632-200012150-00014

Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol 1993; 46: 1417-1432.

DOI: https://doi.org/10.1016/0895-4356(93)90142-N

Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P; ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005; 8: 94-104.

DOI: https://doi.org/10.1111/j.1524-4733.2005.04054.x

Brix ATH, Svensson TM, Sandberg M, Bygum A. Hereditary angioedema: the challenges of cross-border family investigation and treatment. BMJ Case Rep 2020; 13: e231906.

DOI: https://doi.org/10.1136/bcr-2019-231906

Maurer M, Aberer W, Agondi R, Al-Ahmad M, Al-Nesf MA, Ansotegui I, et al. Definition, aims, and implementation of GA2LEN/HAEi angioedema centers of reference and excellence. Allergy 2020; 75: 2115-2123.

DOI: https://doi.org/10.1111/all.14293

Downloads

Published

2021-05-19

How to Cite

Brix, A. T. H., Boysen, H. B., Weller, K., Caballero, T., & Bygum, A. (2021). Patient-reported Outcome Measures for Angioedema: A Literature Review. Acta Dermato-Venereologica, 101(5), adv00456. https://doi.org/10.2340/00015555-3807